Subscribe

Your FREE subscription will give you access to articles, research reports, Biopharma CEO Confidence quarterly reports and much more!

Biopharmaceutical Consulting

The Biopharmaceutical practice at Kineticos assists growth-oriented pharmaceutical and biotech companies realize their commercial potential at the corporate, portfolio and product levels.

The Biopharmaceutical practice at Kineticos supports clients across three service areas including:

Corporate Strategy

Corporate Development

Commercial Strategy

Call us today at 888-986-6960 or send an email to Discover How We Can Elevate Your Business

Ready to learn more about Kineticos successes? Click the Tabs Below for Biopharmaceutical Practice Case Studies, White Papers and Articles, and Blog

 

Case Studies
Articles
Blog
  • Tradeoff Analysis and Valuation

    Situation: A preclinical precision medicine biotech company, looking to leverage their genome editing platform technology, was seeking support in narrowing

     

    Read this Case Study

  • Biosimilar Commercial Assessment

    Situation:  A multinational pharmaceutical company with broad manufacturing capabilities was considering horizontally expanding their portfolio to include biosimilars. Kineticos was

     

    Read this Case Study

  • Forecasting

    Situation: A mid-size pharmaceutical company that unexpectedly obtained a marketed therapy in an adjacent therapeutic area as one of their

     

    Read this Case Study

  • Business Model Analysis

    Situation: A mid-size pharmaceutical company was losing market share and considering withdrawing sales support for one of their products. Due

     

    Read this Case Study

  • Business Modeling

    Situation: A publicly traded pharmaceutical company looking to bolster their existing portfolio asked Kineticos to provide them with a comparative

     

    Read this Case Study

  • Key Opinion Leader Engagement

    Situation: An emerging oncology company with a novel technology requested Kineticos’ support with establishing a development path for their clinically

     

    Read this Case Study

  • Staying the Course

    Written by Mark Osterman, Senior Vice President, Kineticos Kineticos recently announced Q4 2015 results of the Biopharma CEO Confidence Index,

     

    Read this Article

  • Cell and Gene Therapies: The Path to Commercialization

    Article Preview Regenerative Medicine holds enormous potential for treating and ameliorating many chronic conditions for which we do not yet

     

    Read this Article

  • Growth by Acquisition in Life Sciences: Do You Have a Plan?

    Article Preview As the life sciences landscape continually changes, growth by acquisition has become increasingly common. Recent deals, such as

     

    Read this Blog Post

  • R&D Revolutionaries: Why the Actavis/Allergan Deal Takes a Stand for Biopharma’s True Roots in Innovation

    James Forte of Kineticos takes an in-depth look at the recent Actavis/Allergan deal including the role R&D innovation played in shaping the deal’s outcome. Let’s be candid. It’s been awhile since any biopharma company was able to claim R&D as a core competency with a straight face. Biopharma’s R&D efforts have long been challenged, and rightly so given its output, but the Actavis/Allergan deal shows that the right investment in R&D can revolutionize a business. Could efficient R&D be the new definition of innovation?

     

    Read this Blog Post

  • Merck KGaA and Bayer Choose Opposite Strategies

    Article Preview Europe’s two largest chemical and drug conglomerates are changing course in starkly opposite ways. As reported in recent

     

    Read this Blog Post

  • Foundation Medicine and Clovis Expand Partnership

    Article Preview In April 2014, Foundation Medicine and Clovis Oncology announced the expansion of their partnership by developing a companion

     

    Read this Blog Post

  • Role of Companion Diagnostics in Immuno-oncology Race Unfolding

    Article Preview Important oncology events, including ASCO and ESMO, have recently displayed the fruits of the huge investment drug companies

     

    Read this Blog Post

  • Bayer to Divest Plastics Unit to Improve R&D, Acquisition Capacity

    Article Preview As reported by Bloomberg and the Wall Street Journal, Bayer is expected to announce plans to sell its

     

    Read this Blog Post


Contact Us Today to Discover How We Can Elevate Your Business Our Strategy Consulting Services Are Designed to Enhance Your Value

Contact Us Today
Top